Abiopharma

Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer

Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates

Zai Lab Complies with the HFCAA; Not Subject to Delisting*

NASDAQ traded attribute type Financial_Status was changed. Previous value: N. New value: Ontrak, Inc. - Common Stock.

NASDAQ traded attribute type Security_Name was changed. Previous value: 180 Life Sciences Corp. - Warrant. New value: 180 Life Sciences Corp. - Warrant.

NASDAQ traded attribute type Security_Name was changed. Previous value: Ontrak, Inc. - Common Stock. New value: Ontrak, Inc. - Common Stock.

NASDAQ traded attribute type Security_Name was changed. Previous value: 180 Life Sciences Corp. - Common Stock. New value: 180 Life Sciences Corp. - Common Stock.

NASDAQ traded attribute type Financial_Status was changed. Previous value: N. New value: 180 Life Sciences Corp. - Warrant.

NASDAQ traded attribute type Test_mode was changed. Previous value: N. New value: Ontrak, Inc. - Common Stock.

NASDAQ traded attribute type Test_mode was changed. Previous value: N. New value: 180 Life Sciences Corp. - Warrant.

NASDAQ traded attribute type Financial_Status was changed. Previous value: N. New value: 180 Life Sciences Corp. - Common Stock.

NASDAQ traded attribute type Test_mode was changed. Previous value: N. New value: 180 Life Sciences Corp. - Common Stock.

Otero Jose Manuel 🔴 sold 2.8K shares of Lexeo Therapeutics, Inc. (LXEO) at $4.67 Filing ID: 022479

Director Niklason Laura E 🔴 sold 2.2M shares of Humacyte, Inc. (HUMA) at $1.83 ($3.7M) Filing ID: 081008

ADENT JOHN EDWARD 🟡 adjusted position in 0 shares (1 derivative) of NEOGEN CORP (NEOG) at $5.43 Filing ID: 000033